NEW YORK, Jan. 18 (GenomeWeb News) - Decode Genetics has bought Urdur, Verdandi, Skuld, a privately held Icelandic cancer research company, to expand its discovery and drug development capabilities based on population genetics, Decode said today.
"UVS has organized cancer research in
Reykjavik-based Decode acquired UVS for $5.5 million in common stock based on the average closing price for the 30 days preceding the acquisition, according to the statement.
Shares of Decode were trading lower in afternoon trade, after hitting a 52-week high yesterday of $10.77.